• Bristol-Myers Squibb Co., of Princeton, N.J., and Pfizer Inc., of New York, reported results of the six-month Phase III AMPLIFY trial of 5,395 patients with acute venous thromboembolism (VTE), which includes symptomatic deep vein thrombosis (DVT) and/or pulmonary embolism (PE).